Articles tagged "Rejection"

2021 American Transplant Congress
How Should Acute T-Cell Mediated Rejection of Kidney Transplants be Treated?
F. Aziz¹, S. Parajuli², N. Garg², M. Mohamed², A. Djamali², D. Mandelbrot²
¹University of Wisconsin, Madison, WI, ²University of Wisconsin, Verona, WI
*Purpose: Many guidelines suggest treating acute T-cell mediated rejection (TCMR) of kidney allografts that is Banff grade I with steroids alone and Banff grade II…
2021 American Transplant Congress
Clinical Validation and Performance of Donor-Derived Cell-Free DNA in Allograft Rejection
S. Anand¹, A. Pai², J. S. Bromberg³, G. Gupta⁴, I. Moinuddin⁴, T. Alhamad⁵, V. Bowers⁶, S. Ghosh⁷, W. Tian⁷, L. Bu⁸, E. Stites⁹
¹Intermountain Medical Center, Murray, UT, ²University of Texas McGovern Medical School, Houston, TX, ³University of Maryland School of Medicine, Baltimore, MD, ⁴Virginia Commonwealth University, Richmond, VA, ⁵Washington University in St. Louis, St. Louis, MO, ⁶Tampa General Hospital, Tampa, FL, ⁷CareDx, Brisbane, CA, ⁸University of Minnesota, Minneapolis, MN, ⁹University of Colorado, Aurora, CO
*Purpose: Extensive literature regarding the utility of donor-derived cell-free DNA (dd-cfDNA) shares various thresholds for active rejection (AR) based on differing data sets for both…
2021 American Transplant Congress
Non-HLA Antibodies and Eplet Mismatches in Cases with Histological Picture of Antibody-Mediated Rejection with and without HLA Donor-Specific Antibodies
M. Crespo¹, L. Llinás², D. Redondo², C. Butler³, J. Gimeno⁴, M. Pérez-Sáez², A. Buxeda², C. Arias², M. Folgueiras², S. Sanz², N. Valenzuela³, E. E. Reed³, J. Pascual²
¹Nephrology and Kidney Transplantation, Hospital del Mar, Barcelona, Spain, ²Nephrology, Hospital del Mar, Barcelona, Spain, ³UCLA Immunogenetics Center, UCLA, Los Angeles, CA, ⁴Pathology, Hospital del Mar, Barcelona, Spain
*Purpose: Correlation between antibody-mediated rejection (ABMR) and HLA donor-specific antibodies (DSA) is strong but imperfect in kidney transplant (KT) recipients, raising the possibility of other…
2021 American Transplant Congress
Use of Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients: A Scoping Review
A. G. Anderson, M. Eubank, K. Murray
University of Missouri, Columbia, MO
*Purpose: Immune checkpoint inhibitors (ICI) are an emerging treatment for numerous advanced diseases, but their safety and efficacy in immunosuppressed transplant patients is not known.…
2021 American Transplant Congress
Identification of Distinct Blood Monocyte Phenotypes from Transplant Kidney Recipients Undergoing Cellular (TCMR) and Mixed Antibody Mediated Rejection (ABMR)
C. Macedo, E. Bailly, K. Louis, M. Lucas, A. Zeevi, P. Randhawa, D. Metes
Starzl Transplantation Institute, Pittsburgh, PA
*Purpose: Monocytes play an important role in immune defense by initiating adaptive immunity. They are heterogeneous, plastic, and present different subsets: classical (CD14++CD16-), intermediate (CD14+CD16+),…
2021 American Transplant Congress
Intrarenal B-cell Activating Factor (BAFF) Levels are Increased in Transplant Glomerulopathy
S. Panzer, K. Swanson, G. Pandya, L. Hidalgo, S. Reese
University of Wisconsin Madison, Madison, WI
*Purpose: Transplant glomerulopathy (TG), a key feature of chronic active antibody-mediated rejection (caABMR), is associated with allograft failure. B-cell activating factor (BAFF) is a cytokine…
2021 American Transplant Congress
CD40 Blockade by the Fc-Silent Immunosuppressive Antibody Iscalimab Results in Diminished B Cell Activation and Differentiation and is Paralleled by Whole Blood Gene Expression Data
R. Kraaijeveld¹, M. W. van den Hoogen¹, A. E. de Weerd¹, E. Ferroro², G. Robert², U. Laessing², B. Haraldsson², J. S. Rush², C. C. Baan¹
¹Erasmus MC, Rotterdam, Netherlands, ²Novartis Pharmaceuticals AG, Basel, Switzerland
*Purpose: Blockade of costimulatory molecule CD40 by the Fc-silent immunosuppressive drug Iscalimab has shown to inhibit acute alloreactivity in non-human primates and is currently being…
2021 American Transplant Congress
CD56^dimCD16^bright NK Cells from Kidney Transplant Recipients with Antibody-mediated Rejection Display Increased Proliferation, Type-1 Activation and Cytotoxic Profile
E. Bailly¹, C. Macedo¹, K. Louis¹, B. Ramaswami¹, M. Lucas¹, C. Bentlejewski¹, P. Randhawa¹, A. Zeevi¹, C. Lefaucheur², D. Metes¹
¹Department of Surgery, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, ²INSERM UMR-S976. Endothelium, Inflammation & Alloreactivity, Université de Paris, Paris, France
*Purpose: CD56dimCD16bright NK cells are highly potent for cytotoxicity through cell-mediated cytotoxicity (CMC), antibody-dependent cell-mediated cytotoxicity (ADCC) and INF-γ production. The contribution of NK cells…
2021 American Transplant Congress
Naïve Rhesus Monkey CD4⁺CD8^loT Cells Comprise High Percentage of Memory T Cells with Strong Effector Function
M. Kubo, K. Sasaki, A. P. Gutiérrez, L. Lu, V. Vujevich, A. W. Thomson, M. Ezzelarab
Department of Surgery, University of Pittsburgh, PITTSBURGH, PA
*Purpose: Human CD4+CD8loT cells have been reported in patients with organ allograft rejection. We evaluated the incidence, phenotype, and function of CD4+CD8loT cells in nonhuman…
2021 American Transplant Congress
Does the Timing of Subclinical Acute Rejection After Kidney Transplant Matter?
P. Portocarrero¹, S. Park², K. Guo³, L. Zhao³, J. Friedewald²
¹Nephrology, Northwestern University, Chicago, IL, ²Transplant Nephrology, Northwestern University, Chicago, IL, ³Feinberg School of Medicine, Northwestern University, Chicago, IL
*Purpose: We hypothesized that the timing of subclinical acute rejection (subAR) diagnosed with biopsy, gene expression profile or donor-derived cell-free DNA is associated with poor…